Opens in a new tab or window Higher-potency topical corticosteroids, JAK inhibitors, and tacrolimus 0.1% were deemed the most effective topical anti-inflammatory treatments for atopic dermatitis ...

By personifying my eczema and relating to her instead of seeing her as my enemy, I started healing more quickly. I still flare up, but atopic dermatitis no longer controls what I get to do on a ...

"For the millions of people who suffer from atopic dermatitis (AD), or eczema, ENS-002 represents a potential paradigm shift in care." Current treatments like steroids and immunosuppressants may come ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD ... ≥75 percent reduction in the Eczema Area and Severity Index Score (EASI-75) was achieved by 89.1, 84.4 ...

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States. ZORYVE cream 0.15% was approved by the FDA for the ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

Two studies assessed the quality and accuracy of ChatGPT recommendations for atopic dermatitis based on their concordance with clinical guidelines.

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.